




Contents lists available at ScienceDirect

Molecular Immunology

journal homepage: [www.elsevier.com/locate/molimm](http://www.elsevier.com/locate/molimm)



## Viral induction of Zac1b through TLR3- and IRF3-dependent pathways

Barbara Warzée<sup>a</sup>, Claire Mesnil<sup>a</sup>, Didier Hober<sup>b</sup>, Delphine Caloone<sup>b</sup>, Dimitri Pirottin<sup>a</sup>, Mutien-Marie Garigliany<sup>c</sup>, Daniel Desmecht<sup>c</sup>, Pierre-Vincent Drion<sup>d</sup>, Laurent Journot<sup>e</sup>, Pierre Lekeux<sup>a</sup>, Fabrice Bureau<sup>a,1</sup>, Christophe J. Desmet<sup>a,\*,1</sup>

<sup>a</sup> Laboratory of Cellular and Molecular Physiology, GIGA-Research, University of Liege, Liege, Belgium

<sup>b</sup> University Lille 2, Faculty of Medicine, CHRU Lille, Laboratory of Virology/EA3610, Lille 59037, France

<sup>c</sup> Department of Pathology, Faculty of Veterinary Medicine, University of Liege, Liege, Belgium

<sup>d</sup> Département des sciences biomédicales et précliniques, University of Liege, Liege, Belgium

<sup>e</sup> Institut de Génétique Fonctionnelle, Montpellier, France

### ARTICLE INFO

#### Article history:

Received 21 May 2010

Received in revised form 20 August 2010

Accepted 14 September 2010

Available online xxx

#### Keywords:

Zac1

Poly(I:C)

TLR3

IRF3

Virus

### ABSTRACT

Zinc finger protein regulator of apoptosis and cell cycle arrest (Zac1) is a transcription factor able to induce apoptosis or cell cycle arrest through independent pathways. In spite of the important potential functions attributed to Zac1, little is known of its physiological regulation and biological function. We discovered that variant Zac1b was expressed in murine embryonic fibroblasts (MEFs) treated with polyriboinosinic polyribocytidylic acid [poly(I:C)], a synthetic double-stranded RNA. This regulation occurred mainly through Toll-Like Receptor 3 (TLR3)- and Interferon Regulatory Factor 3 (IRF3)-dependent pathways. As TLR3 and IRF3 are central activators of antiviral immunity, we hypothesized that Zac1 may be implicated in antiviral responses. In line with this notion, we observed that Zac1b was expressed in MEFs infected with Encephalomyocarditis virus (EMCV). We also observed that Zac1-deficient MEFs were less sensitive to EMCV-induced cell death than wild-type MEFs. However, Zac1 gene inactivation had no effect on the survival of mice infected with EMCV. In conclusion, this study describes for the first time a transcriptional regulation of Zac1b, induced by synthetic dsRNA and RNA viruses, the functional significance of which remains to be further investigated.

© 2010 Elsevier Ltd. All rights reserved.

### 1. Introduction

Zinc finger protein regulator of apoptosis and cell cycle arrest 1 (Zac1), also called Lost on transformation 1 (Lot1) or Pleiomorphic Adenoma Gene Like 1 (Plagl1), is a vertebrate zinc finger protein transcription factor (Abdollahi et al., 1997b; Spengler et al., 1997; Kas et al., 1998; Varrault et al., 1998). Zac1 mRNA is widely expressed in human and murine organs such as the anterior pituitary gland, other brain areas, the kidney and the adrenal gland (Spengler et al., 1997; Kas et al., 1998; Varrault et al., 1998; Piras et al., 2000). Different splice variants for Zac1 have been identified in human (Kas et al., 1998) and mouse (Huang and Stallcup, 2000). In mice, two variants exist: Zac1a and Zac1b. Zac1b is identical to Zac1a except for 11 additional C-terminal amino acids (Huang and Stallcup, 2000).

Zac1 is a paternally expressed imprinted gene (Kamiya et al., 2000; Piras et al., 2000). Consequently, it is suspected that Zac1 may be implicated in embryonic development, as well as in certain disorders such as neonatal diabetes (Kamiya et al., 2000; Arima et al., 2001; Varrault et al., 2001). In support of such a role, inactivation of the Zac1 gene in mice results in intrauterine growth restriction, altered bone formation and neonatal lethality. Only 30% of Zac1-deficient pups reach adulthood (Varrault et al., 2006). Loss of Zac1 expression has also been observed in numerous tumor types, including breast tumors, ovary tumors and pituitary adenomas (Abdollahi et al., 1997a, 1997b; Pagotto et al., 2000; Cvetkovic et al., 2004; Koy et al., 2004; Basyuk et al., 2005). Thereby, Zac1 has been proposed as a candidate tumor suppressor gene. In support of this hypothesis, overexpression of Zac1 inhibits tumor cell growth through induction of both apoptosis and cell cycle arrest (Spengler et al., 1997; Varrault et al., 1998). Furthermore, Zac1 has been proposed as a co-factor for p53 (Huang et al., 2001), synergizing with it to induce certain anti-proliferative genes such as p21<sup>WAF1/Cip1</sup> or Apoptosis protease-activating factor-1 (Apaf-1) (Huang et al., 2001; Rozenfeld-Granot et al., 2002; Liu et al., 2008). Thus, Zac1 was the first transcription factor beside p53 identified as being able to concurrently induce apoptosis and cell cycle arrest (Spengler et al., 1997).

\* Corresponding author at: Laboratory of Cellular and Molecular Physiology, GIGA-Research, University of Liege, avenue de l'hôpital 1, B34, 4000 Liege, Belgium. Tel.: +32 43663708; fax: +32 43664534.

E-mail address: [Christophe.Desmet@ulg.ac.be](mailto:Christophe.Desmet@ulg.ac.be) (C.J. Desmet).

<sup>1</sup> These authors contributed equally to this work.

In spite of the important potential functions attributed to Zac1, little is known of its physiological regulation. The aims of this study were to identify stimuli that modulate the expression of Zac1, and to investigate the potential functional significance of this regulation. We found that synthetic double-stranded RNA polyriboinosinic polyribocytidylic acid [poly(I:C)] induced expression of Zac1b, mainly through Toll-Like Receptor 3 (TLR3)- and Interferon Regulatory Factor 3 (IRF3)-dependent pathways. As poly(I:C) mimics viral double-stranded (ds)RNA, this result unexpectedly suggested that Zac1b may be implicated in antiviral immunity. We also observed that Zac1b was expressed after infection with Encephalomyocarditis virus (EMCV), and that Zac1-deficient MEFs were modestly but significantly less sensitive to EMCV-induced cell death than wild-type MEFs. However, Zac1-deficient mice did not show any significant changes in their survival rates following EMCV infection. Thus, this study describes for the first time a physiological induction of Zac1b, by synthetic dsRNA and RNA viruses, the functional significance of which remains to be further investigated.

## 2. Materials and methods

### 2.1. Mice

The generation of Zac1-deficient mice has been described previously (Varrault et al., 2006). Zac1-deficient mice were kept on a C57Bl/6 background. Zac1-deficient and wild-type (WT) C57Bl/6 mice were bred and housed in filtered cages in ventilated racks in the institutional conventional facility. Zac1<sup>+/-pat</sup> heterozygous mice were generated by crossing Zac1<sup>+/-</sup> heterozygous males to wild-type C57Bl/6 females. Age-paired groups of mice were used at 8–10 weeks of age. All experimental procedures and protocols were approved by the Institutional Animal Care and Use Committee of the University of Liege. We also followed the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources, National Research Council, and published by the National Academy Press (revised 1996).

### 2.2. Murine embryonic fibroblasts

WT, Zac1<sup>-/-</sup>, and IRF3<sup>-/-</sup> MEFs were isolated from 12.5 to 13.5 days postcoitum mouse embryos. The embryos were dissociated and digested with trypsin/EDTA (GIBCO/Invitrogen) to produce single-cell suspensions. IRF3-deficient mice (Sato et al., 2000) were purchased from RIKEN BioResource Center. Mice were bred and maintained in specific pathogen-free conditions. TLR3<sup>-/-</sup> and TLR3<sup>+/+</sup> MEFs were a kind gift from the Professor S. Akira (Osaka University, Osaka, Japan). MEFs were cultured in Dulbecco's Minimal Essential Medium (DMEM) complemented with 10% fetal bovine serum, 2 mM L-glutamin, 0.1 mM non-essential amino acids, 10 µg/ml gentamycin and 10 µg/ml β-mercaptoethanol (GIBCO/Invitrogen).

### 2.3. Reagents

Actinomycin D, doxorubicin, H<sub>2</sub>O<sub>2</sub>, recombinant murine Interferon-β1 (IFN-β1), and nutlin-3a were from Sigma–Aldrich. CpG, flagellin, Pam3CSK4, poly(I:C) and R848 were from InvivoGen. Lipopolysaccharide (LPS) was from Calbiochem. Recombinant murine Interferon (IFN)-α (hybrid IFN-α1/α4) was from Hycult Biotechnology, recombinant murine Interleukin (IL)-1β from Biosource/Invitrogen, and recombinant murine Tumor Necrosis Factor (TNF)-α from PeproTech.

### 2.4. Cell irradiation

Cells were irradiated with 10 Gy of gamma irradiation (Caesium-137) using a Gammacell-40 Irradiator (MDS Nordion) or with UV irradiation (50 J/m<sup>2</sup>).

### 2.5. Murine peritoneal macrophages

Seven- to ten-week-old C57BL/6 mice were treated intraperitoneally with poly(I:C) or vehicle (PBS). Mice were sacrificed 6 h after treatment and peritoneal cells were obtained by peritoneal lavages with PBS/EDTA (GIBCO/Invitrogen). Cell counts showed that approximately 85% of isolated cells were macrophages.

### 2.6. Viruses

Encephalomyocarditis virus (EMCV) was obtained from the American Type Culture Collection (ATCC, chimpanzee, Florida, 1944) and Vesicular stomatitis virus (VSV, strain Indiana) was a kind gift from Professor P. Lebon (Paris University, Paris, France). The viruses were propagated in Vero cells (ATCC). When more than 90% of the infected cells showed signs of cytopathy, the cultures were frozen and thawed twice, and the culture medium was clarified by low-speed centrifugation. Virus titers in culture medium were measured by serial dilution in Vero cells to determine the tissue culture infective dose 50 (TCID<sub>50</sub>) using the Reed–Muench method. The viral stocks were stored at -80 °C in DMEM medium (GIBCO/Invitrogen).

Sendai virus (SeV) (ATCC, lung material from fatal case of newborn pneumonitis, Japan, 1952) was propagated in 11-day-old chick embryos for 48 h and viral stocks were titrated in LLC-MK2 cells (ATCC), as described previously (Faisca et al., 2005).

### 2.7. Transfections and plasmids

For the transduction of Zac1a and Zac1b, Zac1a and Zac1b cDNAs were cloned into the pcDNA3.1 expression vector (Invitrogen). Cells were transfected overnight with 3 µg of pcDNA3.1-Zac1a, pcDNA3.1-Zac1b, or empty vector using 6 µl of TransFectin (Bio-Rad), as recommended by the manufacturer.

For the poly(I:C) transfection experiments, cells were transfected for 6 h with 3 µg of poly(I:C) using 6 µl of TransFectin (Bio-Rad), as recommended by the manufacturer.

### 2.8. Immunoblotting

Cells were lysed in RIPA buffer [1× PBS, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 5 mM EDTA, 1 mM PMSF, 100 µM sodium orthovanadate, 5 µg/ml aprotinin, 5 µg/ml leupeptin (Sigma), 40 µg/ml Complete (Roche)]. The lysates were clarified and protein amounts were determined by Lowry protein assay (Bio-Rad). Equivalent amounts of whole cell lysates were subjected to SDS-PAGE and proteins were electrotransferred to polyvinylidene difluoride membranes (Amersham). The membranes were blocked for 1 h at room temperature with 5% milk in 1× TBS with 0.1% Tween 20 and incubated overnight at 4 °C with polyclonal murine anti-Zac1 antibody (rabbit polyclonal IgG, Santa-Cruz), polyclonal murine anti-p53 antibody (rabbit polyclonal IgG, Santa-Cruz), or monoclonal anti-β-actin (mouse monoclonal IgM, EMB Biosciences). The blots were then incubated for 45 min with HRP-conjugated secondary antibody. Immunoreactive bands were revealed using the ECL detection method (Amersham). Band intensities were estimated by densitometry using the Quantity One software (Bio-Rad). The data were normalized to β-actin and are expressed as mean ± SD (Standard Deviation) from three independent experiments. Results were expressed as fold induction compared with untreated cells (values in untreated cells set to 1).

## 2.9. RNA extraction and real-time RT-PCR

Total RNA was extracted from cells using NucleoSpin® RNA II extraction kits (Macherey-Nagel) and was reverse transcribed with Transcriptor First Strand cDNA Synthesis kit (Roche) according to the manufacturer's instructions. PCR was then performed with the following primers: Zac1b-F 5-tgagtgtgtgaatctggg-3 and Zac1b-R 5-ttatctaataatcgctgatggaaa-3; GAPDH-F 5-caacagggtgtggacctcat-3 and GAPDH-R 5-tgggataggcctctcttct-3. Real-time PCR analysis was performed on cDNA samples using iQ SYBR Green Supermix (Bio-Rad) and the iQ5 real-time PCR detection system (Bio-Rad). The comparative threshold cycle method was used to quantify the relative levels of gene expression and was normalized to the house-keeping gene GAPDH.

## 2.10. Immunoassay

The concentration of IFN- $\alpha$  and IFN- $\beta$  in cell supernatants and sera was measured using enzymelinked immunosorbent assays (ELISAs) kits (PBL InterferonSource), as recommended by the manufacturer.

## 2.11. MTT assay

Cell viability was determined by 3-(4,5)-dimethylthiazolium(-z)-y1)-3,5-di-phenyltetrazoliumromide (MTT) assay (Sigma). Culture medium was removed and MEFs were incubated with MTT solution [0.5 mg/ml in DMEM without phenol red (GIBCO/Invitrogen)] at 37 °C for 3 h. Then, the converted dye was solubilized with acidic isopropanol (0.04 M HCl in absolute isopropanol). Absorbance of the converted dye was measured by spectrophotometry at a wavelength of 570 nm with background subtraction at 630 nm.

## 2.12. BrdU assay


Cell proliferation was measured by bromodeoxyuridine (BrdU) assay according to the manufacturer's instructions (BD Biosciences). Briefly, cells were incubated for 3 h with BrdU at a final concentration of 10  $\mu$ M in cell culture medium. Then, cells were fixed, permeabilized and treated with DNase to expose incorporated BrdU. Cells were resuspended with fluorescent anti-BrdU antibody. Total DNA was stained for cell cycle analysis with 7-amino-actinomycin D (7-AAD) solution. Analysis was performed by flow cytometry with FACScanto II (Becton Dickinson).

## 2.13. TUNEL assay

Apoptosis was measured by Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay according to the manufacturer's instructions (Roche). Cells were fixed, permeabilized and labeled with TUNEL reaction mixture. Analysis was performed by flow cytometry using a FACScanto II (Becton Dickinson).

## 2.14. Statistical analyses

All experiments were repeated three times and data are expressed as mean  $\pm$  SD (standard deviation). Statistical significance of differences was determined by ANOVA followed by Fisher's PLSD (Protected Least Significant Difference) tests. A generalized Wilcoxon test was used to test for differences in survival between wild-type and Zac1-deficient mice after EMCV infection. Differences were considered statistically significant at  $p < 0.05$ .



**Fig. 1.** DNA damage inducers do not induce Zac1 expression. WT MEFs were treated for 6 h with H<sub>2</sub>O<sub>2</sub> (200  $\mu$ M),  $\gamma$ -irradiation (10 Gy), doxorubicin (0.2  $\mu$ g/ml), nutlin-3a (5  $\mu$ M) or UV irradiation (50 J/m<sup>2</sup>). For reference, WT MEFs were transfected overnight with Zac1a or Zac1b expression vectors. Total protein extracts were analyzed for Zac1 and p53 expression by Western blotting.  $\beta$ -Actin was used as loading control. Comparable results were obtained in three independent experiments. (\*) Significantly different from untreated control cells.

## 3. Results


### 3.1. DNA damage inducers do not induce Zac1 expression

Zac1 has been proposed to act as a tumor suppressor, as it notably shares the ability to induce concurrently apoptosis and cell cycle arrest with p53 (Spengler et al., 1997). We thus initially studied the effect of DNA damage inducers on Zac1 expression in mouse embryonic fibroblasts (MEFs). Surprisingly, H<sub>2</sub>O<sub>2</sub>,  $\gamma$ -irradiation, doxorubicin, nutlin-3a and UV irradiation did not induce Zac1 protein expression, although, as expected, they induced the accumulation of p53 (Fig. 1).

### 3.2. Poly(I:C) induces Zac1b expression mainly through TLR3- and IRF3-dependent mechanisms

Next, we sought to determine whether pro-inflammatory stimuli, which may act as potent apoptosis inducers (Rath and Aggarwal, 1999; Salaun et al., 2006; Ma et al., 2007; Grunnet et al., 2009; Taura et al., 2010), could regulate Zac1 expression. MEFs were stimulated with various TLR ligands [Pam3CSK4 (TLR1/2), poly(I:C) (TLR3), LPS (TLR4), flagellin (TLR5), R848 (TLR7/8), CpG (TLR9)] and pro-inflammatory cytokines (TNF- $\alpha$ , IL-1 $\beta$ ), and assessed for their expression of Zac1. As shown in Fig. 2A, the TLR3 ligand poly(I:C) uniquely induced Zac1 protein expression. The induction of Zac1 by poly(I:C) was time-dependent, starting 3 h, peaking 6 h and going back to baseline 12 h post-treatment (Fig. 2B). None of the other treatments induced Zac1 at any of the time points tested (data not shown).

To determine which of the two murine variant transcripts of Zac1 was induced by poly(I:C), we transfected MEFs with expression vectors coding for Zac1a or Zac1b. Western blot analysis showed that Zac1a and Zac1b had molecular weights of approximately 105 kDa and 125 kDa (Fig. 2C). Comparison with exogenously expressed Zac1 isoforms indicated that poly(I:C) induced predominantly the Zac1b isoform in MEFs. The anti-Zac1 antibody also recognized a non-specific band of approximately 140 kDa, which we suspect could be the enzyme Myosin light chain kinase (MYLK) based on molecular weight and sequence homology with the immunogen used for anti-Zac1 antibody production (Fig. 2C).



**Fig. 2.** Poly(I:C) induces Zac1b expression. (A) WT MEFs were stimulated for 6 h with Pam3CSK4 (1 μg/ml, TLR1/2 ligand), poly(I:C) (20 μg/ml, TLR3 ligand), LPS (10 μg/ml, TLR4 ligand), flagellin (10 μg/ml, TLR5 ligand), R848 (5 μg/ml, TLR7/8 ligand), CpG (5 μM, TLR9 ligand), TNF-α (20 ng/ml) or IL-1β (10 ng/ml). Total protein extracts were analyzed for Zac1 expression by Western blotting. β-Actin was used as loading control. (B) WT MEFs were stimulated for 1, 3, 6, 8, 12 and 24 h with poly(I:C) (20 μg/ml). Vehicle-treated cells were used as control. Total protein extracts were analyzed for Zac1 expression by Western blotting. β-Actin was used as loading control. (C) WT MEFs were transfected overnight with Zac1a or Zac1b expression vectors. For comparison, Zac1<sup>+/+</sup> and Zac1<sup>-/-</sup> MEFs were treated for 6 h with poly(I:C) (20 μg/ml). Total protein extracts were analyzed for Zac1 expression by Western blotting. β-Actin was used as loading control. (°) Non-specific band. (\*) Significantly different from untreated control. (D) WT MEFs were stimulated for 6 h with poly(I:C), with or without actinomycin D (1 μg/ml). Zac1b mRNA expression was estimated by real-time RT-PCR. Results were expressed as fold induction compared with untreated WT MEFs (values in untreated WT MEFs set as 1). The data were normalized to GAPDH and are expressed as mean ± SD. All experiments were repeated three times.


Poly(I:C) induced the expression of Zac1b also at the mRNA level (Fig. 2D). This appeared to depend on transcriptional mechanisms, as the upregulation of Zac1b mRNA expression was abolished by concomitant treatment with actinomycin D (Fig. 2D).

We next investigated whether poly(I:C) also induced Zac1b expression in primary adult cell types. In this regard, we observed that intraperitoneal injection of mice with poly(I:C) led to Zac1b expression in peritoneal macrophages (Fig. 3A and B).


Poly(I:C) is a synthetic double-strand RNA that, if deposited extracellularly, activates TLR3 (Alexopoulou et al., 2001) while, if transfected, activates RIG-I (retinoic acid-inducible gene 1 protein)-like helicases (RLHs) (Yoneyama et al., 2004; Gitlin et al., 2006; Kato et al., 2006). Through subsequent activation of the transcription factor IRF3 (O'Neill et al., 2003; Yamamoto et al., 2004), poly(I:C) notably induces type I IFN expression (Yoneyama et al., 1998). To examine the pathway used by poly(I:C) to induce Zac1b, we treated TLR3<sup>-/-</sup> and WT MEFs with poly(I:C), either deposited in the medium or transfected into the cells. Zac1b was induced by both deposited and transfected poly(I:C) in WT MEFs. However, the induction was much less pronounced in transfected cells (Fig. 4A and B). The induction by poly(I:C) was abolished in TLR3<sup>-/-</sup> MEFs when poly(I:C) was deposited, but not when it was transfected. These results thus indicate that the expression of Zac1b is most potently activated by TLR3-dependent mechanisms, although intracellular recognition mechanisms may also contribute to its induction.

We next investigated the contribution of IRF3 to TLR3-induced expression of Zac1b. We observed that the expression of Zac1b


was strongly decreased in poly(I:C)-treated IRF3<sup>-/-</sup> MEFs, indicating that Zac1b induction by deposited poly(I:C) depended on classical TLR3/IRF3 signaling (Fig. 5A and B). However, treatment of MEFs with type I IFNs (IFN-α and IFN-β) did not induce




**Fig. 3.** Poly(I:C) induces Zac1b expression in peritoneal macrophages. Three WT mice were treated intraperitoneally with poly(I:C) (200 μg) or vehicle (PBS). Six hours after treatment, peritoneal macrophages were obtained by peritoneal lavage. (A) Zac1b mRNA expression was estimated by real-time RT-PCR. Results were expressed as fold induction compared with peritoneal macrophages of vehicle-treated mice (values in peritoneal macrophages of vehicle-treated mice set as 1). The data were normalized to GAPDH and are expressed as mean ± SD from three independent experiments. (B) Total protein extracts were analyzed for Zac1 expression by Western blotting. β-Actin was used as loading control. Comparable results were obtained in three independent experiments. (\*) Significantly different from untreated control.



**Fig. 4.** Poly(I:C) induces Zac1b expression mostly through TLR3-dependent mechanisms. TLR3<sup>+/+</sup> and TLR3<sup>-/-</sup> MEFs were stimulated for 6 h with deposited (20 μg/ml) or transfected poly(I:C). (A) Zac1b mRNA expression was estimated by real-time RT-PCR. Results were expressed as fold induction compared with untreated MEFs (values in untreated MEFs set as 1). The data were normalized to GAPDH and are expressed as mean ± SD from three independent experiments. (B) Total protein extracts were analyzed for Zac1 expression by Western blotting. β-Actin was used as loading control. Comparable results were obtained in three independent experiments. (\*) Significantly different from untreated control.



**Fig. 5.** Poly(I:C) induces Zac1b expression through IRF3-dependent, type I IFN-independent mechanisms. IRF3<sup>+/+</sup> and IRF3<sup>-/-</sup> MEFs were stimulated for 6 h with poly(I:C) (20 μg/ml). WT MEFs were stimulated for 6 h with IFN-α or IFN-β (100 U/ml). (A and C) Zac1b mRNA expression was estimated by real-time RT-PCR. Results were expressed as fold induction compared with untreated MEFs (values in untreated MEFs set as 1). The data were normalized to GAPDH and are expressed as mean ± SD from three independent experiments. (B and D) Total protein extracts were analyzed for Zac1 expression by Western blotting. β-Actin was used as loading control. Comparable results were obtained in three independent experiments. (\*) Significantly different from untreated control. (E and F) Zac1<sup>+/+</sup> and Zac1<sup>-/-</sup> MEFs were stimulated for 24 h with poly(I:C) (20 μg/ml). (E) IFN-α and (F) IFN-β concentrations in cell supernatants were measured by ELISAs. Data are expressed as means ± SD of three independent experiments.



**Fig. 6.** Zac1<sup>-/-</sup> MEFs are less sensitive to EMCV-induced cell death than Zac1<sup>+/+</sup> MEFs. (A) WT MEFs were infected for 6 h with EMCV, VSV or SeV virus [0.1 or 1 Multiplicity of Infection (M.O.I.)]. Total protein extracts were analyzed for Zac1 expression by Western blotting.  $\beta$ -Actin was used as loading control. Comparable results were obtained in three independent experiments. (B) TLR3<sup>+/+</sup> and TLR3<sup>-/-</sup> MEFs were infected for 6 h with EMCV (0.1 or 1 M.O.I.). Total protein extracts were analyzed for Zac1 expression by Western blotting.  $\beta$ -Actin was used as loading control. Comparable results were obtained in three independent experiments. (\*) Significantly different from untreated control. (C) Zac1<sup>+/+</sup> and Zac1<sup>-/-</sup> MEFs were infected for 12 h with EMCV (0.1 or 1 M.O.I.). Cell viability was determined by MTT assay. Data are expressed as mean percentage of uninfected MEFs  $\pm$  SD. Comparable results were obtained in three independent experiments. (D and E) Zac1<sup>+/+</sup> and Zac1<sup>-/-</sup> MEFs were infected for 6 h with EMCV (0.1 or 1 M.O.I.). (D) Cell proliferation was determined by BrdU assay and (E) cell apoptosis was determined by TUNEL assay. Data are expressed as means  $\pm$  SD of three independent experiments.

Zac1b expression (Fig. 5C and D). Thus, Zac1b expression upon TLR3 stimulation is independent on type I IFN production. We also assessed whether Zac1b induction by poly(I:C) impacted on type I IFN production by comparing IFN- $\alpha$  and IFN- $\beta$  production in WT and Zac1<sup>-/-</sup> MEFs. As shown in Fig. 5E and F, there was no effect of Zac1 deletion on poly(I:C)-induced type I IFN production.

### 3.3. Zac1<sup>-/-</sup> MEFs are less sensitive to EMCV-induced cell death than Zac1<sup>+/+</sup> MEFs


Because Zac1 expression is regulated by TLR3 and IRF3, and possibly RLHs, which are central activators of antiviral immunity, the previous results unexpectedly suggested that Zac1b might be implicated in antiviral responses. We thus first examined whether viral infection induced Zac1b expression. We focused on RNA viruses, as TLR3 and RLHs primarily recognize their dsRNA replication intermediates (Alexopoulou et al., 2001; Yoneyama et al., 2004; Gitlin et al., 2006; Kato et al., 2006). MEFs were infected with three RNA viruses, namely Encephalomyocarditis virus (EMCV), Vesicular stomatitis virus (VSV) and Sendai virus (SeV), and assessed for Zac1 expression. Western blot analyses showed that Zac1b was induced by infection with EMCV, but not with VSV or SeV (Fig. 6A). The EMCV-induced upregulation of Zac1b was totally abolished in

TLR3<sup>-/-</sup> MEFs (Fig. 6B), indicating that TLR3 is the primary inducer of Zac1b upon EMCV infection.

As Zac1 has mainly been described as a pro-apoptotic factor (Spengler et al., 1997; Varrault et al., 1998), we next investigated whether the upregulation of Zac1 would impact on the survival of EMCV-infected cells. Survival tests showed that Zac1<sup>-/-</sup> MEFs indeed were modestly but significantly less sensitive to EMCV-induced cell death than WT MEFs (Fig. 6C). However, this increased survival of Zac1<sup>-/-</sup> MEFs was due neither to an increase in cell proliferation, nor to a decrease in apoptosis (Fig. 6D and E). The identification of the exact mechanisms by which Zac1 may regulate cell survival will thus require further experimentation. Of note, similar cell death rates were observed when WT or Zac1<sup>-/-</sup> MEFs were infected with VSV or SeV, or treated with the DNA damaging agents H<sub>2</sub>O<sub>2</sub> and doxorubicin (Fig. 7A–D), indicating that the effects observed with EMCV were specifically due to differential Zac1 expression. Again, Zac1 expression did not impact on type I IFN production upon EMCV infection, as WT and Zac1<sup>-/-</sup> MEFs expressed similar levels of IFN- $\alpha$  and IFN- $\beta$  (Fig. 8A and B).

### 3.4. Zac1<sup>+/-pat</sup> mice do not show significant changes in their survival rates following EMCV infection

Because Zac1 is maternally imprinted, Zac1<sup>+/-pat</sup> heterozygotes mice inheriting a wild-type allele from their mother are deficient



**Fig. 7.** *Zac1*<sup>-/-</sup> MEFs are not less sensitive to VSV-, SeV-, H<sub>2</sub>O<sub>2</sub>- and doxorubicin-induced cell death than *Zac1*<sup>+/+</sup> MEFs. (A–D) *Zac1*<sup>+/+</sup> and *Zac1*<sup>-/-</sup> MEFs were infected for 24 h with (A) VSV or (B) SeV (0.1 or 1 M.O.I.), or treated for 24 h with (C) H<sub>2</sub>O<sub>2</sub> (200 or 1000 μM) or (D) doxorubicin (0.2 or 1 μg/ml). Cell viability was determined by MTT assay. Data are expressed as mean percentage of untreated MEFs ± SD. Comparable results were obtained in three independent experiments.

for *Zac1* expression (Varrault et al., 2006). In agreement with previous reports (Varrault et al., 2006), we also observed that *Zac1* mRNA was not expressed in several organs from *Zac1*<sup>+/-pat</sup> mice such as liver or lung (data not shown). *Zac1*<sup>+/-pat</sup> heterozygous were thus considered equivalent to null mutants throughout this study.

To observe the effect of the *Zac1* gene inactivation on the survival of mice, we have infected *Zac1*<sup>+/+</sup> and *Zac1*<sup>+/-pat</sup> mice with EMCV. As shown in Fig. 9A–C, *Zac1*<sup>+/-pat</sup> mice did not show significant changes in their survival rates following EMCV infection. Also the production of type I IFNs upon EMCV infection was similar between *Zac1*<sup>+/+</sup> and *Zac1*<sup>+/-pat</sup> mice (Fig. 9D and E).


#### 4. Discussion

In spite of the important potential functions attributed to *Zac1*, little is known of its physiological regulation and its biological function. Although *Zac1* is quite ubiquitously expressed at the mRNA level, detection of its protein product does not always follow the expression pattern of its mRNA. Furthermore, it remained unknown whether *Zac1* expression could be regulated transcriptionally, under which circumstances this regulation occurs, and what the functional consequences of this regulation, if any, could be.


*Zac1* and p53 share the ability to induce concurrently apoptosis and cell cycle arrest through different and independent pathways (Spengler et al., 1997). Because of its functional parallelism with p53, and because p53 is highly expressed in response to DNA damage-inducing agents such as H<sub>2</sub>O<sub>2</sub>, γ-irradiations, doxorubicin, nutlins and UV irradiations (Van Dyke, 2007), we initially tested the effect of DNA damage inducers on *Zac1* expression in MEFs. Surprisingly, *Zac1* expression was not induced under any of the conditions tested, whereas p53 was potentially induced as expected. These results thus indicate that in spite of their similar functions, *Zac1* undergoes a different regulation than p53.

Some pro-inflammatory stimuli may act as potent inducers of apoptosis (Rath and Aggarwal, 1999; Ma et al., 2007; Grunnet et al., 2009). We thus sought to determine whether strong pro-inflammatory stimuli such as TNF-α, IL-1β, or TLR ligands could regulate *Zac1* expression. The pro-inflammatory cytokines had no effect on *Zac1* induction. Unique among the TLR ligands tested, poly(I:C), a specific TLR3 ligand, induced *Zac1* protein in MEFs. Analysis of the protein and transcript of *Zac1* in poly(I:C)-treated MEFs indicated that mainly the *Zac1b* isoform was induced. As MEFs are embryonic cells, which could limit the interpretation of the results obtained in these cells, we studied the induction of *Zac1b* by poly(I:C) in primary adult cells. We showed that peritoneal macrophages from mice treated intraperitoneally with poly(I:C) expressed *Zac1b*, thus ruling out cell-type specific effects of the regulation.

We next dissected the signaling pathway triggered by poly(I:C) to induce *Zac1b* expression. Poly(I:C) may activate TLR3 signaling, as well as intracellular recognition pathways involving RLHs,



**Fig. 8.** *Zac1* does not regulate type I IFN production upon EMCV infection. (A and B) *Zac1*<sup>+/+</sup> and *Zac1*<sup>-/-</sup> MEFs were infected for 24 h with EMCV (0.1 or 1 M.O.I.). (A) IFN-α and (B) IFN-β concentrations in cell supernatants were measured by ELISAs. Data are expressed as means ± SD of three independent experiments.



**Fig. 9.** *Zac1*<sup>+/-pat</sup> mice do not show significant changes in their survival rates or type I IFN production following EMCV infection. (A–C) The survival of *Zac1*<sup>+/+</sup> and *Zac1*<sup>+/-pat</sup> mice infected intraperitoneally with (A) 10, (B) 100 or (C) 1000 plaque-forming units (pfu) of EMCV was monitored through time ( $n = 8$ /group). A generalized Wilcoxon test was used to test for differences in survival. Comparable results were obtained in two independent experiments. (D–E) *Zac1*<sup>+/+</sup> and *Zac1*<sup>+/-pat</sup> mice were injected intraperitoneally with  $10^7$  pfu of EMCV ( $n = 6$ /group). Sera were collected 6 h after injection. (D) IFN- $\alpha$  and (E) IFN- $\beta$  production levels were determined by ELISA. Data are expressed as means  $\pm$  SD of three independent experiments.

depending on its cellular localization in endosomal vesicles or in the cytoplasm, respectively (Alexopoulou et al., 2001; Yoneyama et al., 2004; Gitlin et al., 2006; Kato et al., 2006). We thus compared *Zac1* induction upon exposure of MEFs to deposited or transfected poly(I:C), and used TLR3<sup>-/-</sup> MEFs to estimate the contribution of both pathways. We could show that poly(I:C) most potently induced *Zac1b* through a classical TLR3-dependent pathway, while intracellular recognition may also upregulate *Zac1* expression, but with much less potency. Interestingly, induction of *Zac1b* was dependent on IRF3, as shown by its reduced expression in poly(I:C)-treated IRF3<sup>-/-</sup> MEFs, but independent on autocrine type I IFN signaling, as treatment of MEFs with recombinant IFN- $\alpha$  and IFN- $\beta$  failed to induce its expression. Thus, *Zac1b* might be under the direct transcriptional control of IRF3. Notably, whereas *Zac1b* induction by deposited poly(I:C) was completely abolished in TLR3-deficient MEFs, it was still faintly induced in IRF3-deficient MEFs, at least at the mRNA level, indicating that mechanisms additional to IRF3 may regulate *Zac1b* expression downstream of TLR3. Of note as well, *Zac1* did not impact on type I IFN induction by poly(I:C).

TLR3 and RLHs are central activators of antiviral immunity that are activated by viral dsRNA replication intermediates (Alexopoulou et al., 2001; Yoneyama et al., 2004; Gitlin et al., 2006; Kato et al., 2006). We thus examined whether infection with RNA viruses, namely EMCV (Picornaviridae), VSV (Rhabdoviridae) and SeV (Paramyxoviridae) induced *Zac1b* expression. We observed that only infection with EMCV induced *Zac1b* expression. One explanation for the differential effect of EMCV compared to VSV and SeV might lie in the fact that they trigger different RLH pathways. Indeed, EMCV is thought to be detected mainly by MDA5, while VSV and SeV would be sensed mostly by RIG-I (Gitlin et al., 2006; Kato et al., 2006; Saito and Gale, 2008). However, we observed that TLR3 was the main *Zac1b* inducer in EMCV-infected cells, which makes this explanation less likely. Another explanation could be that VSV and SeV inhibit the induction of type I IFNs in MEFs, through undefined mechanisms (Kato et al., 2006). Thus, like other viruses, VSV and SeV might inhibit IRF3 activity (Basler et al., 2003; Cardenas et al., 2006), which could explain that they do not induce *Zac1b*. In contrast, EMCV potently stimulates IRF3 activity (Kato et al., 2006), which we showed promotes *Zac1b* expression.

Finally, we investigated the potential functional significance of *Zac1b* expression during EMCV infection. As *Zac1* has mainly been described as a pro-apoptotic factor (Spengler et al., 1997; Varrault et al., 1998), we studied whether the upregulation of *Zac1* would impact on the survival of EMCV-infected cells. We showed that *Zac1*<sup>-/-</sup> MEFs were only mildly, but yet significantly, less sensitive to EMCV-induced cell death than *Zac1*<sup>+/+</sup> MEFs. However, we could not find a straightforward explanation for this observation. Indeed, *Zac1* did not seem to impact on the proliferation and apoptosis rates of EMCV-infected cells. Of note, EMCV infection mostly leads to the necrosis of the cells (Schwarz et al., 1998; Huang et al., 2009), and apoptosis rates were accordingly very low in our experiments. We also could show that *Zac1* does not impact on type I IFN expression upon EMCV infection. Thus, it is probable that *Zac1* impacts on the survival of EMCV-infected cells through as yet unidentified mechanisms unrelated to apoptosis. We however could show that the survival advantage conferred to *Zac1*-deficient cells upon EMCV infection was not related to a general increase in resistance to cell death. Indeed, *Zac1*<sup>-/-</sup> MEFs displayed survival rates similar to *Zac1*<sup>+/+</sup> MEFs in response to H<sub>2</sub>O<sub>2</sub> or doxorubicin.

*In vivo*, EMCV infects preferentially cardiomyocytes and induces their necrosis, which eventually leads to the death of the infected animal (Kato et al., 2006). On the other hand, death of infected cells can also limit viral replication and dissemination, increasing host resistance to infection (Takaoka et al., 2003). We thus wondered what the effect, if any, of the inactivation of the *Zac1* gene might be on the survival of mice infected with EMCV. We did not observe any significant change between survival rate or type I IFN production of *Zac1*<sup>+/+</sup> and *Zac1*<sup>+/-pat</sup> mice following EMCV infection. Thus, although *Zac1* has some mild effect on the course of EMCV infection *in vitro*, its role during viral infection *in vivo* remains undefined. A possible explanation may lie in differences in the biology of cardiomyocytes *in vivo* compared to MEFs, the latter indeed being cultured proliferating embryonic cells.

In conclusion, this study identifies and characterizes for the first time a physiological induction of *Zac1b*. Indeed, we show that *Zac1b* is regulated through TLR3-, IRF3-, and possibly RLHs-dependent pathways, and is induced by viral infection. *Zac1* however does not impact on the course of viral infection *in*



*vivo*. Its exact physiological function thus remains to be further investigated.

## Acknowledgements

We thank Profs T. Taniguchi, S. Akira and P. Lebon for providing respectively IRF3<sup>-/-</sup> mice, TLR3<sup>-/-</sup> MEFs and VSV virus. We are also grateful to Drs. Jacques Piette, Alain Chariot, Jean-Christophe Marine and Yvette Habraken for helpful advice. The authors also thank Dr. Sandra Ormenese and the Cell Imaging and Flow Cytometry GIGA Technological Platform for FACS analyses, Dr. Didier Cataldo for Western blotting band intensities measurement and Raja Fares, Cédric François, Fabrice Olivier and Ilham Sbai for technical and secretarial assistance. The Laboratory of Cellular and Molecular Physiology is supported by grants of the Fonds National de la Recherche Scientifique (FRS-FNRS; Belgium; Mandat d'Impulsion Scientifique), by the Fonds de la Recherche Scientifique Médicale (FRSM; Belgium), by the Belgian Programme on Interuniversity Attraction Poles (IUAP; FEDIMMUNE) initiated by the Belgian State (Belgian Science Policy), and by an Action de Recherche Concertée de la Communauté Française de Belgique. B. Warzée is a research fellow at the Fonds pour la formation à la Recherche dans l'Industrie et dans l'Agriculture (FRIA; Belgium). C. Mesnil is a research fellow and C.J. Desmet is a post-doctoral researcher of the FRS-FNRS.

## References

- Abdollahi, A., Godwin, A.K., Miller, P.D., Getts, L.A., Schultz, D.C., Taguchi, T., Testa, J.R., Hamilton, T.C., 1997a. Identification of a gene containing zinc-finger motifs based on lost expression in malignantly transformed rat ovarian surface epithelial cells. *Cancer Res.* 57, 2029–2034.
- Abdollahi, A., Roberts, D., Godwin, A.K., Schultz, D.C., Sonoda, G., Testa, J.R., Hamilton, T.C., 1997b. Identification of a zinc-finger gene at 6q25: a chromosomal region implicated in development of many solid tumors. *Oncogene* 14, 1973–1979.
- Alexopoulou, L., Holt, A.C., Medzhitov, R., Flavell, R.A., 2001. Recognition of double-stranded RNA and activation of NF- $\kappa$ B by Toll-like receptor 3. *Nature* 413, 732–738.
- Arima, T., Drewell, R.A., Arney, K.L., Inoue, J., Makita, Y., Hata, A., Oshimura, M., Wake, N., Surani, M.A., 2001. A conserved imprinting control region at the HYMAI/ZAC domain is implicated in transient neonatal diabetes mellitus. *Hum. Mol. Genet.* 10, 1475–1483.
- Basler, C.F., Mikulasova, A., Martinez-Sobrido, L., Paragas, J., Muhlberger, E., Bray, M., Klenk, H.D., Palese, P., Garcia-Sastre, A., 2003. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. *J. Virol.* 77, 7945–7956.
- Basyuk, E., Coulon, V., Le Digarcher, A., Coisy-Quivy, M., Moles, J.P., Gandarillas, A., Journot, L., 2005. The candidate tumor suppressor gene ZAC is involved in keratinocyte differentiation and its expression is lost in basal cell carcinomas. *Mol. Cancer Res.* 3, 483–492.
- Cardenas, W.B., Loo, Y.M., Gale Jr., M., Hartman, A.L., Kimberlin, C.R., Martinez-Sobrido, L., Saphire, E.O., Basler, C.F., 2006. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. *J. Virol.* 80, 5168–5178.
- Cvetkovic, D., Pisarcik, D., Lee, C., Hamilton, T.C., Abdollahi, A., 2004. Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer. *Gynecol. Oncol.* 95, 449–455.
- Faisca, P., Anh, D.B., Desmecht, D.J., 2005. Sendai virus-induced alterations in lung structure/function correlate with viral loads and reveal a wide resistance/susceptibility spectrum among mouse strains. *Am. J. Physiol. Lung Cell Mol. Physiol.* 289, L777–L787.
- Gitlin, L., Barchet, W., Gilfillan, S., Cella, M., Beutler, B., Flavell, R.A., Diamond, M.S., Colonna, M., 2006. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. *Proc. Natl. Acad. Sci. U.S.A.* 103, 8459–8464.
- Grunnet, L.G., Aikin, R., Tonnesen, M.F., Paraskevas, S., Blaabjerg, L., Stirling, J., Rosenberg, L., Billestrup, N., Maysinger, D., Mandrup-Poulsen, T., 2009. Proinflammatory cytokines activate the intrinsic apoptotic pathway in beta-cells. *Diabetes* 58, 1807–1815.
- Huang, C.H., Vallejo, J.G., Kollias, G., Mann, D.L., 2009. Role of the innate immune system in acute viral myocarditis. *Basic Res. Cardiol.* 104, 228–237.
- Huang, S.M., Schonthal, A.H., Stallcup, M.R., 2001. Enhancement of p53-dependent gene activation by the transcriptional coactivator Zac1. *Oncogene* 20, 2134–2143.
- Huang, S.M., Stallcup, M.R., 2000. Mouse Zac1, a transcriptional coactivator and repressor for nuclear receptors. *Mol. Cell. Biol.* 20, 1855–1867.
- Kamiya, M., Judson, H., Okazaki, Y., Kusakabe, M., Muramatsu, M., Takada, S., Takagi, N., Arima, T., Wake, N., Kamimura, K., Satomura, K., Hermann, R., Bonthron, D.T., Hayashizaki, Y., 2000. The cell cycle control gene ZAC/PLAGL1 is imprinted—a strong candidate gene for transient neonatal diabetes. *Hum. Mol. Genet.* 9, 453–460.
- Kas, K., Voz, M.L., Hensen, K., Meyen, E., Van de Ven, W.J., 1998. Transcriptional activation capacity of the novel PLAG family of zinc finger proteins. *J. Biol. Chem.* 273, 23026–23032.
- Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu, S., Jung, A., Kawai, T., Ishii, K.J., Yamaguchi, O., Otsu, K., Tsujimura, T., Koh, C.S., Reis e Sousa, C., Matsuura, Y., Fujita, T., Akira, S., 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. *Nature* 441, 101–105.
- Koy, S., Hauses, M., Appelt, H., Friedrich, K., Schackert, H.K., Eckelt, U., 2004. Loss of expression of ZAC/LOT1 in squamous cell carcinomas of head and neck. *Head Neck* 26, 338–344.
- Liu, P.Y., Chan, J.Y., Lin, H.C., Wang, S.L., Liu, S.T., Ho, C.L., Chang, L.C., Huang, S.M., 2008. Modulation of the cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by Zac1 through the antagonistic regulators p53 and histone deacetylase 1 in HeLa Cells. *Mol. Cancer Res.* 6, 1204–1214.
- Ma, Y., Haynes, R.L., Sidman, R.L., Vartanian, T., 2007. TLR8: an innate immune receptor in brain, neurons and axons. *Cell Cycle* 6, 2859–2868.
- O'Neill, L.A., Fitzgerald, K.A., Bowie, A.G., 2003. The Toll-IL-1 receptor adaptor family grows to five members. *Trends Immunol.* 24, 286–290.
- Pagotto, U., Arzberger, T., Theodoropoulou, M., Gruber, Y., Pantaloni, C., Saeger, W., Losa, M., Journot, L., Stalla, G.K., Spengler, D., 2000. The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. *Cancer Res.* 60, 6794–6799.
- Piras, G., El Kharroubi, A., Kozlov, S., Escalante-Alcalde, D., Hernandez, L., Copeland, N.G., Gilbert, D.J., Jenkins, N.A., Stewart, C.L., 2000. Zac1 (Lot1), a potential tumor suppressor gene, and the gene for epsilon-sarcoglycan are maternally imprinted genes: identification by a subtractive screen of novel uniparental fibroblast lines. *Mol. Cell. Biol.* 20, 3308–3315.
- Rath, P.C., Aggarwal, B.B., 1999. TNF-induced signaling in apoptosis. *J. Clin. Immunol.* 19, 350–364.
- Rozenfeld-Granot, G., Krishnamurthy, J., Kannan, K., Toren, A., Amariglio, N., Givol, D., Rechavi, G., 2002. A positive feedback mechanism in the transcriptional activation of Apaf-1 by p53 and the coactivator Zac-1. *Oncogene* 21, 1469–1476.
- Saito, T., Gale Jr., M., 2008. Differential recognition of double-stranded RNA by RIG-I-like receptors in antiviral immunity. *J. Exp. Med.* 205, 1523–1527.
- Salaun, B., Coste, I., Risoan, M.C., Lebecque, S.J., Renno, T., 2006. TLR3 can directly trigger apoptosis in human cancer cells. *J. Immunol.* 176, 4894–4901.
- Sato, M., Suemori, H., Hata, N., Asagiri, M., Ogasawara, K., Nakao, K., Nakaya, T., Katsuki, M., Noguchi, S., Tanaka, N., Taniguchi, T., 2000. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN- $\alpha$ /beta gene induction. *Immunity* 13, 539–548.
- Schwarz, E.M., Badorff, C., Hiura, T.S., Wessely, R., Badorff, A., Verma, I.M., Knowlton, K.U., 1998. NF- $\kappa$ B-mediated inhibition of apoptosis is required for encephalomyocarditis virus virulence: a mechanism of resistance in p50 knock-out mice. *J. Virol.* 72, 5654–5660.
- Spengler, D., Villalba, M., Hoffmann, A., Pantaloni, C., Houssami, S., Bockaert, J., Journot, L., 1997. Regulation of apoptosis and cell cycle arrest by Zac1, a novel zinc finger protein expressed in the pituitary gland and the brain. *EMBO J.* 16, 2814–2825.
- Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., Taniguchi, T., 2003. Integration of interferon- $\alpha$ /beta signalling to p53 responses in tumour suppression and antiviral defence. *Nature* 424, 516–523.
- Taura, M., Fukuda, R., Suico, M.A., Eguma, A., Koga, T., Shuto, T., Sato, T., Morino-Koga, S., Kai, H., 2010. TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis. *Cancer Sci.*
- Van Dyke, T., 2007. p53 and tumor suppression. *N. Engl. J. Med.* 356, 79–81.
- Varrault, A., Bilanges, B., Mackay, D.J., Basyuk, E., Ahr, B., Fernandez, C., Robinson, D.O., Bockaert, J., Journot, L., 2001. Characterization of the methylation-sensitive promoter of the imprinted ZAC gene supports its role in transient neonatal diabetes mellitus. *J. Biol. Chem.* 276, 18653–18656.
- Varrault, A., Ciani, E., Apiou, F., Bilanges, B., Hoffmann, A., Pantaloni, C., Bockaert, J., Spengler, D., Journot, L., 1998. hZAC encodes a zinc finger protein with antiproliferative properties and maps to a chromosomal region frequently lost in cancer. *Proc. Natl. Acad. Sci. U.S.A.* 95, 8835–8840.
- Varrault, A., Gueydan, C., Delalbre, A., Bellmann, A., Houssami, S., Aknin, C., Severac, D., Chotard, L., Kahli, M., Le Digarcher, A., Pavidis, P., Journot, L., 2006. Zac1 regulates an imprinted gene network critically involved in the control of embryonic growth. *Dev. Cell.* 11, 711–722.
- Yamamoto, M., Takeda, K., Akira, S., 2004. TIR domain-containing adaptors define the specificity of TLR signaling. *Mol. Immunol.* 40, 861–868.
- Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., Taira, K., Akira, S., Fujita, T., 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. *Nat. Immunol.* 5, 730–737.
- Yoneyama, M., Suhara, W., Fukuhara, Y., Fukuda, M., Nishida, E., Fujita, T., 1998. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. *EMBO J.* 17, 1087–1095.